247 related articles for article (PubMed ID: 23588143)
1. Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases.
De Simone C; Sollena P; Coco V; Caldarola G
G Ital Dermatol Venereol; 2013 Apr; 148(2):175-84. PubMed ID: 23588143
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
4. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
5. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.
Hession MT; Gottlieb AB
J Dermatolog Treat; 2011 Apr; 22(2):90-101. PubMed ID: 20673155
[TBL] [Abstract][Full Text] [Related]
6. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
7. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
9. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
Fiorino G; Allez M; Malesci A; Danese S
Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis and Inflammatory Bowel Disease.
Cottone M; Sapienza C; Macaluso FS; Cannizzaro M
Dig Dis; 2019; 37(6):451-457. PubMed ID: 31079092
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease.
Andrisani G; Guidi L; Papa A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):890-901. PubMed ID: 22953637
[TBL] [Abstract][Full Text] [Related]
12. Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents.
Guerra I; Gisbert JP
Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):41-8. PubMed ID: 23265148
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
[TBL] [Abstract][Full Text] [Related]
14. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
15. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
[TBL] [Abstract][Full Text] [Related]
16. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis in patients with psoriasis.
Gulliver W
Br J Dermatol; 2008 Aug; 159 Suppl 2():2-9. PubMed ID: 18700909
[TBL] [Abstract][Full Text] [Related]
18. Disease-related and drug-induced skin manifestations in inflammatory bowel disease.
Hindryckx P; Novak G; Costanzo A; Danese S
Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):203-214. PubMed ID: 28095714
[TBL] [Abstract][Full Text] [Related]
19. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
Melo FJ; Magina S
Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
